Two Republican members of Congress are urging the Trump administration to give the National Guard a formal role in protecting the
Intellia Therapeutics rose sharply after reporting successful late-stage results for its experimental gene-editing treatment for hereditary angioedema, a rare disorder that
Tesla reported first-quarter results that beat Wall Street expectations and used the moment to signal an even bigger long-term investment push.
Moderna has begun a late-stage clinical trial of its experimental bird flu vaccine in the United States and the United Kingdom,
President Donald Trump’s aggressive deportation campaign could become a political liability for Republicans in the 2026 midterm elections. More Americans now
A major shift in how the Trump administration is approaching federal research funding, with consequences that could reach far beyond universities
Scientists have produced a new reconstruction of the Grand Canyon’s geological history, offering fresh insight into how one of the world’s
Senator Elizabeth Warren is pressing the U.S. government to examine whether Nvidia’s acquisition of SchedMD, the developer behind the widely used
Amazon Web Services has launched a new artificial intelligence platform designed to accelerate one of the slowest parts of pharmaceutical research:
Eli Lilly’s newly approved weight-loss pill has cleared an important regulatory hurdle, but the U.S. Food and Drug Administration is requiring
Never miss any important news. Subscribe to our newsletter.
The New York Finance is the premier platform for bold innovation, visionary leadership, and next-generation entrepreneurship. Dive into compelling stories of emerging ventures, market game-changers, and influential leaders redefining the business landscape. Stay informed with exclusive rankings, strategic insights, and the key trends shaping the global financial future.
Never miss any important news. Subscribe to our newsletter.
Copyright 2026 - The New York Finance - All rights reserved.
Never miss any important news. Subscribe to our newsletter.
